Assignment: Treatment of Substance-Related and Addictive Disorders Hallucinogen -Related Disorders Required Readings( Need 3 + reference). Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). (11th ed.). Philadelphia, PA: Wolters Kluwer. · Chapter 20, “Substance Use and Addictive Disorders” (pp. 616–693) Alcohol abstinence Alcohol dependence Alcohol withdrawal Nicotine addiction Opioid dependence Reversal of    benzodiazepine effects acamprosate disulfiram nalmefene naltrexone chlordiazepoxide clonidine clorazepate diazepam lorazepam oxazepam bupropin varenicline buprenorphine naltrexone flumazenil Required Media The approximate length of this media piece is 69 minutes. : The approximate length of this media piece is 126 minutes. Optional Resources Bechtold, J., Simpson, T., White, H. R., & Pardini, D. (2015). Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychology of Addictive Behaviors, 29(3), 552–563. doi:10.1037/adb0000103 You will access this article from the Walden Library databases. · Chapter 46, “Alcohol-Related Disorders” · Chapter 47, “Sedative-, Hypnotic-, or Anxiolytic-Related Disorders” · Chapter 48, “Opioid-Related Disorders: Opioid Detoxification” · Chapter 49, “Opioid-Related Disorders: Antagonist Treatment” · Chapter 50, “Opioid-Related Disorders: Agonist Maintenance Treatment” · Chapter 51, “Hallucinogen-Related Disorders · Chapter 52, “Cannabis-Related Disorders” · Chapter 53, “Club Drug Addiction” · Chapter 54, “Stimulant-Related Disorders” · Chapter 55, “Nicotine-Related Disorders” · Chapter 56, “Individual Therapy for Substance Use Disorders” · Chapter 57, “Cognitive, Behavioral, and Motivational Therapies for Substance Use Disorders” · Chapter 58, “Group Therapy for Substance Use Disorders” · Chapter 59, “Family Therapy in Substance Abuse Treatment” · Chapter 60, “Network Therapy for Substance Use Disorders” · Chapter 61, “Pain and Addiction” · Chapter 62, “Gambling Disorder”

Treatment of Substance-Related and Addictive Disorders

Hallucinogen-Related Disorders

Hallucinogen-related disorders are a category of substance-related and addictive disorders that are characterized by the use of hallucinogenic drugs, such as LSD, psilocybin mushrooms, and mescaline. These drugs induce profound alterations in perception, mood, and cognition, often resulting in hallucinations, changes in sensory perception, and alterations in thought processes.

The treatment of hallucinogen-related disorders involves a comprehensive approach that addresses both the acute effects of the drug as well as the long-term consequences of its use. This may include medical management of symptoms, psychotherapy, and support groups.

Medical management of symptoms typically involves addressing any immediate physical or psychological effects of the hallucinogen. This may include the use of medications to manage hallucinations, anxiety, or other psychiatric symptoms that may arise as a result of drug use. Some common medications that may be used in the treatment of hallucinogen-related disorders include antipsychotics, benzodiazepines, and antidepressants.

Psychotherapy is an integral component of the treatment of hallucinogen-related disorders and may take many different forms. Cognitive behavioral therapy (CBT) and motivational interviewing are often used to help individuals recognize and change their thinking patterns and behaviors related to drug use. These therapies can help individuals develop healthier coping mechanisms and strategies to prevent relapse.

Support groups can also be beneficial for individuals with hallucinogen-related disorders. Support groups provide an opportunity for individuals to share their experiences, receive support from others who have similar struggles, and learn from each other’s successes and challenges. These groups may be led by a mental health professional or facilitated by individuals in recovery.

In addition to medical and psychosocial interventions, there are also emerging treatments for hallucinogen-related disorders that show promise. One such treatment is psychedelic-assisted therapy, which involves the use of hallucinogens under controlled conditions in conjunction with psychotherapy. This approach has shown promising results in the treatment of certain psychiatric disorders, such as post-traumatic stress disorder (PTSD) and treatment-resistant depression.

Overall, the treatment of hallucinogen-related disorders requires a multimodal approach that addresses the individual’s physical, psychological, and social needs. This may involve a combination of medication, psychotherapy, support groups, and emerging treatment modalities.

References

Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.

Bechtold, J., Simpson, T., White, H. R., & Pardini, D. (2015). Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychology of Addictive Behaviors, 29(3), 552–563. doi:10.1037/adb0000103